



Please amend claims 4, 16, 17, and 22 as follows:

4. A conformationally restricted polyamine analog selected from the group consisting of:



and



and any salt or stereoisomer thereof.


16. The polyamine analog of claim 4, further comprising a pharmaceutically acceptable excipient.

17. A method of treating an indication in an individual comprising the step of administering to the individual a therapeutic amount of a polyamine analog of claim 4.

22. A method of suppressing cell growth in an individual comprising the step of administering to the individual a therapeutic amount of a polyamine analog of claim 4.


Please add new claims 32-34 as follows:

32. A conformationally restricted polyamine analog according to claim 4 of the formula:



and any salt thereof.

33. A conformationally restricted polyamine analog according to claim 4 of the formula:



and any salt thereof.

34. The method of claim 17, wherein the indication is breast cancer.

REMARKS

With the entry of the amendments above, claims 4, 16-23, and 32-34 are pending in this application. Claim 4 has been amended to stand as the first independent claim presented; claims 16, 17 and 22 have been amended to depend from claim 4 instead of cancelled claim 1. New claims 32 and 33 are supported by original claim 4 and at page 7, lines 10-14 of the instant specification. New claim 34 is supported by original claim 20 and at page 14, lines 27-28 of the instant specification. No new matter has been added by these amendments. No fees are believed